inclusion body myositis


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

inclusion body myositis

a slowly progressive inflammatory myopathy with a male predominance and preferential weakness onset in the quadriceps muscles, finger flexors, or pharyngeal muscles. Inflammatory infiltrate can be observed, with a predominance of CD8+ T cells.

inclusion body myositis

a progressive inflammatory myopathy primarily involving muscles of the pelvic region and legs, usually seen in older people. The muscles are infiltrated by mononuclear inflammatory cells, sarcoplasmic vacuoles, masses of filaments and filamentous microtubules, and sometimes eosinophilic bodies.

inclusion body myositis

A type of idiopathic myositis that is not autoimmune and does not respond to immunosuppressive therapy, a clinical diagnosis of exclusion, confirmed by typical histologic features Clinical Slowly progressive disease of middle-aged ♂, beginning in legs, causing atrophy and weakness of quadriceps, sparing facial and oropharyngeal muscles EMG Abnormal electrical 'irritation', slowing of nerve conduction and ↑ wave amplitude
Mentioned in ?
References in periodicals archive ?
The report assesses Inclusion Body Myositis (IBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
Nature of "Tau" immunoreactivity in normal myonuclei and inclusion body myositis.
Unlike most connective tissue diseases, inclusion body myositis occurs predominantly in men.
The results will be abnormal in both conditions, but MRIs from patients with inclusion body myositis are more likely to show fatty infiltration and atrophy and more widespread abnormalities, while in polymyositis, the predominant abnormality seen on MRI is inflammation distributed along the fascia.
Sporadic inclusion body myositis and hereditary inclusion body myositis.
Ubiquitin immunostaining and inclusion body myositis: study of 30 patients with inclusion body myositis.
A snapshot of the global therapeutic scenario for Inclusion Body Myositis (IBM).
Coverage of the Inclusion Body Myositis (IBM) pipeline on the basis of route of administration and molecule type.
Summary of Bcl-2, Bcl-X, and Bax Immunoreactivity in Inclusion Body Myositis (N = 27) Degene- Regene- Subsar- rating rating Autophagic colemmal Antibody Inflammation Fibers Fibers Vacuoles Staining Bax 26 (96) * 24 (89) 24 (89) 24 (89) 21 (78) Bcl-2 27 (100) 2 (7) 21 (78) 2 (7) 6 (22) Bcl-x 8 (30) 3 (11) 4 (15) 3 (11) 1 (4) * Values are expressed as number positive (%).
Mitochondrial deletions in inclusion body myositis.